Comparative Pharmacology
Head-to-head clinical analysis: PEMETREXED DITROMETHAMINE versus PEMFEXY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEMETREXED DITROMETHAMINE versus PEMFEXY.
PEMETREXED DITROMETHAMINE vs PEMFEXY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA and RNA synthesis.
500 mg/m2 intravenously over 10 minutes every 21 days.
500 mg/m2 intravenously over 10 minutes on day 1 of a 21-day cycle, in combination with cisplatin.
None Documented
None Documented
Terminal half-life 3.5 hours (range 2.5-5.0 hours) in patients with normal renal function; prolonged to 5-10 hours in moderate renal impairment. Clinical context: Half-life is dose-independent; clearance correlates with creatinine clearance.
Terminal elimination half-life ~17 hours (range 13-26 hours) in patients with normal renal function; prolonged to >24 hours in renal impairment. Supports every-21-day dosing.
Primarily renal excretion: 70-90% of the dose is eliminated unchanged in urine within 24 hours. Fecal excretion accounts for <5%.
Renal excretion (70-90% unchanged drug), biliary/fecal (<5%)
Category C
Category C
Antineoplastic Antifolate
Antineoplastic Antifolate